SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank50
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P50
Within normal range
vs 5Y Ago
-0.1x
Contraction
Streak
1 yr
Consecutive growthAccelerating
PeriodValue
2025-30.57%
2024-36.52%
2023-7.08%
2022-1280.73%
2021-80.14%
2020208.58%
20190.00%